CD80 and neoplasm: CTLA-4 inhibitors exert anti-tumor effects by preventing Tregs from down-regulating CD80/86 expression and depleting Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP) (78).